Findings

What do systematic reviews say?

47 questions · 52 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 9.6%GRADE not reported 0 · 0%Very low 7 · 13.5%Low 26 · 50%Moderate 6 · 11.5%High 8 · 15.4%

Memantine vs placebo

Core symptoms of autism · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Very low

Memantine vs placebo

Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD

Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
OR 0.64 [0.17, 2.39]
2 studies · 144 participants
Low

Memantine vs placebo

Language · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 144 participants
Low

Memantine vs placebo

Memory (specific cognitive function) · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Adaptive behaviour · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Hyperactivity · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Irritability · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Efficacy: number of participants who respond to treatment ‐ at 3 months · adults (aged 18 years+) with depression in bipolar disorder

It is very uncertain whether memantine changes efficacy: number of participants who respond to treatment ‐ at 1 week compared with placebo (very low certainty).

4 findings from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.08 [0.06, 19.05]
1 study · 29 participants
Very low
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 4.88 [0.78, 30.29]
1 study · 29 participants
Very low
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 5.33 [1.02, 27.76]
1 study · 29 participants
Very low

Show 1 more finding

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.66 [0.69, 4.03]
2 studies · 261 participants
Low

Memantine vs placebo

Remission · adults (aged 18 years+) with depression in bipolar disorder

It is very uncertain whether memantine changes efficacy: number of participants who achieve remission ‐ at 1 week compared with placebo (very low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.08 [0.06, 19.05]
1 study · 29 participants
Very low

Memantine vs placebo

Depressive symptoms · adults (aged 18 years+) with depression in bipolar disorder

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

Memantine vs placebo

Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder

Memantine showed no clear difference in acceptability: total dropouts compared with placebo (low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 0.77 [0.45, 1.31]
2 studies · 261 participants
Low

Memantine vs placebo

Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder

Memantine showed no clear difference in acceptability: dropouts due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 0.34 [0.01, 8.34]
1 study · 232 participants
Low

Memantine vs placebo

Carer stress · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Institutional/home care · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Death · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Secondary outcome measure: cognitive abilities at the end of · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 184 participants
Low

Memantine vs placebo

Behavioural problems: overall · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Low

Memantine vs placebo

Adverse events · people with Down syndrome

Comparison 2: memantine showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
OR 0.45 [0.18, 1.17]
2 studies · 211 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Cognitive function · people with dementia

2 findings from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 344 participants
Low
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Moderate

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Dropout due to lack of efficacy of trial medication or deterioration in overall medical condition · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in dropout due to lack of efficacy of trial medication or deterioration… compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 1.53 [0.84, 2.76]
4 studies · 583 participants
Low